KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Short-term Investments (2016 - 2025)

Gsk (GSK) has 6 years of Short-term Investments data on record, last reported at $161.3 million in Q4 2023.

  • For Q4 2023, Short-term Investments fell 27.6% year-over-year to $161.3 million; the TTM value through Dec 2023 reached $161.3 million, down 27.6%, while the annual FY2023 figure was $161.7 million, 31.24% down from the prior year.
  • Short-term Investments reached $161.3 million in Q4 2023 per GSK's latest filing, down from $222.9 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $541.3 million in Q4 2019 and bottomed at $161.3 million in Q4 2023.
  • Average Short-term Investments over 3 years is $308.5 million, with a median of $222.9 million recorded in 2022.
  • Peak YoY movement for Short-term Investments: surged 400.78% in 2019, then fell 27.6% in 2023.
  • A 3-year view of Short-term Investments shows it stood at $541.3 million in 2019, then tumbled by 58.83% to $222.9 million in 2022, then fell by 27.6% to $161.3 million in 2023.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $161.3 million in Q4 2023, $222.9 million in Q4 2022, and $541.3 million in Q4 2019.